Bayer starts Phase II trial of investigational GIRK4 inhibitor in atrial fibrillation
Bayer initiated a Phase II study of an investigational GIRK4 inhibitor in patients with atrial fibrillation.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.